1. Home
  2. ASTL vs CGEM Comparison

ASTL vs CGEM Comparison

Compare ASTL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Algoma Steel Group Inc.

ASTL

Algoma Steel Group Inc.

HOLD

Current Price

$3.55

Market Cap

467.0M

Sector

Industrials

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$12.69

Market Cap

794.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTL
CGEM
Founded
1902
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
467.0M
794.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ASTL
CGEM
Price
$3.55
$12.69
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$30.11
AVG Volume (30 Days)
1.3M
756.0K
Earning Date
03-11-2026
03-10-2026
Dividend Yield
1.37%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$25.68
$79.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$5.68
52 Week High
$7.25
$16.74

Technical Indicators

Market Signals
Indicator
ASTL
CGEM
Relative Strength Index (RSI) 35.51 40.60
Support Level $3.54 $11.43
Resistance Level $4.77 $13.21
Average True Range (ATR) 0.27 0.83
MACD -0.09 -0.38
Stochastic Oscillator 12.98 1.27

Price Performance

Historical Comparison
ASTL
CGEM

About ASTL Algoma Steel Group Inc.

Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: